Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification.

Haematologica
Lingzhi YanSuning Chen

Abstract

Among 4,780 consecutive adult acute lymphoblastic/myeloblastic leukemia patients, we identified 117 (2.4%) patients with mixed-phenotype acute leukemia fulfilling WHO 2008 criteria; these were classified as: Blymphoid+ myeloid (n=64), T-lymphoid+myeloid (n=38), B+T-lymphoid (n=14) and trilineage (n=1). Of 92 patients karyotyped, 59 were abnormal and were classified as: complex (22 of 92), t(9;22)(q34;q11) (14 of 92), monosomy 7 (7 of 92), polysomy 21 (7 of 92), t(v;11q23) (4 of 92), t(10;11)(p15;q21) (3 of 92), while STIL-TAL1 fusion was detected in one (T+My) patient. After investigating common acute leukemia-related mutations in 17 genes, 12 of 31 (39%) patients were found to have at least one mutation, classified with: IKZF1 deletion (4 of 31), and EZH2 (3 of 31), ASXL1 (3 of 31), ETV6 (2 of 31), NOTCH1 (1 of 31), and TET2 (1 of 31) mutations. Array-CGH revealed genomic deletions of CDKN2A (4 of 12), IKZF1 (3 of 12), MEF2C (2 of 12), BTG1 (2 of 12), together with BCOR, EBF1, K-RAS, LEF1, MBNL1, PBX3, and RUNX1 (one of 12 each). Our results indicate that mixed-phenotype acute leukemia is a complex entity with heterogeneous clinical, immunophenotypic, cytogenetic, and molecular genetic features.

References

Jan 1, 1988·Leukemia Research·G J Ruiz-ArgüellesA Marín-López
Jul 6, 2007·Leukemia·E G WeirM J Borowitz
Aug 29, 2009·Haematologica·Amal S Al-SeraihyAsim F Belgaumi
Feb 4, 2010·Blood·Alejandro GutierrezA Thomas Look
Nov 11, 2011·Genes, Chromosomes & Cancer·Catarina LundinBertil Johansson

❮ Previous
Next ❯

Citations

Nov 16, 2013·Nature Reviews. Drug Discovery·Jonas W HøjfeldtKristian Helin
Oct 23, 2013·Annals of Hematology·Marcela Deffis-CourtErick Crespo-Solís
Jul 10, 2014·Leukemia & Lymphoma·Hongjie ShenSuning Chen
Mar 9, 2013·Leukemia & Lymphoma·Qinling MaYinjun Lou
Sep 25, 2015·Clinical Nuclear Medicine·Saeed ElojeimyMarguerite T Parisi
Feb 24, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Reinhold MunkerUNKNOWN Center for International Blood and Marrow Transplant Research
Jul 31, 2013·British Journal of Haematology·Kalliopi N Manola
Apr 22, 2015·European Journal of Haematology·Jane L Liesveld
Apr 23, 2014·European Journal of Haematology·Hiroaki ShimizuYoshihisa Nojima
Jan 22, 2015·European Journal of Haematology·Hiroaki ShimizuUNKNOWN Kanto Study Group for Cell Therapy (KSGCT)
Mar 18, 2015·Nature Reviews. Clinical Oncology·Kathryn G Roberts, Charles G Mullighan
Apr 11, 2015·Leukemia Research·Runhua Shi, Reinhold Munker
Jan 22, 2015·Blood·Ofir Wolach, Richard M Stone
Dec 2, 2014·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Jaehyup KimHung S Luu
Apr 21, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard M Stone
Jan 23, 2016·American Journal of Hematology·Preetesh JainNaval Daver
Sep 13, 2016·Iranian Journal of Pediatrics·Ghasem Miri-AliabadAkbar Dorgalaleh
Jan 19, 2017·Current Opinion in Hematology·Ofir Wolach, Richard M Stone
Apr 20, 2017·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Martin CernanZuzana Pikalova
Apr 5, 2018·Leukemia & Lymphoma·Matthew M KlairmontJoel F Gradowski
Oct 27, 2017·Archives of Pathology & Laboratory Medicine·Nathan J Charles, Daniel F Boyer
Oct 27, 2017·Genome Research·Tin NguyenSorin Draghici
Oct 18, 2018·American Journal of Hematology·Firas El ChaerAshkan Emadi
Jun 1, 2019·Epigenomics·Annalisa AstolfiAndrea Pession
Oct 2, 2012·The Journal of Clinical Investigation·Charles G Mullighan
Apr 30, 2019·Cytometry. Part B, Clinical Cytometry·Anna Porwit, Marie C Béné
Jan 9, 2020·Current Opinion in Hematology·Ofir Wolach, Richard M Stone
Mar 4, 2020·American Journal of Hematology·Sanjay S Patel, Olga K Weinberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.